The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Bispecifics in NHL: epcoritamab and glofitamab
Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, shares some insights into the promise of bispecific antibodies for the treatment of non-Hodgkin lymphoma, drawing focus on the promising results obtained with the use of epcoritamab and glofitamab. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
